The Open Group October Virtual Event To Celebrate 25 Years of Open Technology Standards
19.10.2021 11:00:00 EEST | Business Wire | Press release
The Open Group, the vendor-neutral technology standards consortium, is hosting its upcoming “Open Digital Standards” event October 25 – 27, 2021.
The Open Digital Standards event will bring together vendors and end-user organizations from across the globe to discuss how the cross-industry development of open standards is helping businesses become digital-first.
The virtual event will start at 11:30 am Shanghai local time on Tuesday October 26 (8:30 pm PDT October 25), and finish at 1:30 pm local time in Boston on Wednesday October 27. Regional sessions will be hosted in their local languages by all The Open Group offices throughout the globe – Shanghai, Mumbai, London, Sao Paulo, San Francisco, Tokyo, Johannesburg, Boston.
Presentations on Tuesday will focus on the work of The TOGAF® Standard and impact of the UNIX® Standard. Throughout the day, speakers from organizations such as Chevron, NGINX Inc., Capgemini Insights & Data, and National Air Traffic Services, will join TOGAF® Standard Product Manager Sonia Gonzales and Chair of The Open Group ArchiMate® Forum Jean-Baptiste Sarrodie to explore the changing role of Enterprise Architects (EA) and the evolution and impact of ArchiMate®. Presentations will provide practical examples of how these standards are being applied within a range of industries to improve business efficiency.
On Wednesday, attendees will have the opportunity to hear from The Open Group CDO Dave Lounsbury and Micro Focus CTO Dr. Lars Rossen about open standards for the digital enterprise and agile world. Sessions in the afternoon will feature speakers from L3Harris and Lockheed Martin and explore the implications of open technical standards applicable to military and commercial sensor systems including the FACE™ Consortium and SOSA™ Consortium and the recent launch of the Technical Standard for SOSA™ Reference Architecture, Edition 1.0.
Continuing on in the afternoon, Dr. Jack Freund, Head of Cyber Risk Methodology at VisibleRisk, will discuss the value of risk analysis and provide practical guidance on the Open FAIR™ approach, a model and taxonomy for understanding, analyzing, and measuring information risk.
Key speakers at the event include:
- Steve Nunn, President & CEO, The Open Group
- James de Raeve, Vice President, The Open Group
- Junkyo (Jack) Fujieda, Representative and Chairman, The Open Group Japan
- Dr. Pallab Saha, General Manager, The Open Group India
- Stuart Macgregor, Chief Executive, The Open Group South Africa and Real IRM Solutions
- Roberto Severo, Country Manager, The Open Group Brazil
- Andras Szakal, CTO, The Open Group
- Hiroki Habuka, Deputy Director for Global Digital Governance, Ministry of Economy, Trade and Industry, Japan (METI)
- Regine Deleu, General Manager (Digital Architecture), Auckland Transport, Govt of New Zealand
- Patrick Kelly, Product Leader, Chevron
- Kartik Ravel, Senior Director, Digital Transformation Services, Fujitsu
- Dr. Che Haiping, Senior Vice President, Chief Digital Transformation Officer, Huawei Technologies
Additional key topics of discussion include:
- The Role of Standards in a Data Economy – On Tuesday, J. Satyanarayana, Chief Advisor, C4IR India, World Economic Forum Member, Advisory Board, Global Forum on Cyber Expertise (GFCE), Netherlands, will discuss how the use of standards spanning the entire data lifecycle becomes a strategic imperative to accelerate the transition to a data and a digital economy
- Standards in Action: TOGAF, Open FAIR, Open Agile Architecture – On Tuesday, Peter Haviland, Chief Information and Operating Officer, Angle Finance, will recount some hits and misses over the past 15 years contributing to and using The Open Group standards
- Product Integrity and Global Supply Chain Security – On Wednesday, Joanne Woytek, NASA SEWP Program Director, will provide a synopsis of key factors in Supply Chain Risk Management for Acquisition of IT solutions by the US Government with applicability to similar Global market acquisition activities
- A Data-Driven Approach to Environmental Footprint and Sustainability: How Open Footprint impacts GHG Alignment – In various regional sessions, a panel of Open Footprint™ Forum (OFP) experts will discuss why there is a business imperative to address the challenges and current gaps additionally with an overview of what are the global and local challenges followed by what OFP is aiming to address
Agenda and registration details can be found here.
-ENDS-
About The Open Group
The Open Group is a global consortium that enables the achievement of business objectives through technology standards. Our diverse membership of more than 850 organizations includes customers, systems and solutions suppliers, tool vendors, integrators, academics, and consultants across multiple industries. Further information on The Open Group can be found at www.opengroup.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211019005076/en/
Contact information
Meghan Marks
Senior Programme Manager, Hotwire
UKOpengroup@hotwirepr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
